Nurse Practitioner · Park Ridge, IL
NPI
1326510884
Since 2018
Specialty
Nurse Practitioner
Code 363L00000X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
1875 Dempster St Ste 625
Park Ridge, IL, 60068
Phone (847) 723-4088
Groups this clinician bills Medicare through
Medicare paid, 2024
$21K
273 services
Medicare patients, 2024
129
Average age 78
Drug cost, 2024
$1.5M
2,514 prescriptions
Company payments, 2025
$215
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Catherine M Claro was code 99215 (office e&m - established), 106 times for 99 patients. In total Catherine M Claro billed 273 services in 5 codes, and Medicare paid $21K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-02-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 106 | 99 | $120.90 | $13K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 89 | 83 | $11.15 | $992 |
| 99443 Telephone Services | Office | 61 | 45 | $94.71 | $5,777 |
By year: 2022 $37K for 293 services; 2023 $42K for 332 services; 2024 $21K for 273 services.
Medicare prescription drug claims, 2024
In 2024, the drug Catherine M Claro prescribed most often to Medicare patients was Carbidopa-Levodopa Er (Carbidopa/Levodopa), with 353 prescriptions and refills. In total Catherine M Claro wrote 2,514 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 353 | 845 | 122 | $14K |
| Carbidopa-Levodopa-Entacapone Carbidopa/Levodopa/Entacapone | 345 | 657 | 87 | $94K |
| Carbidopa-Levodopa Carbidopa/Levodopa | 258 | 503 | 70 | $9,184 |
| Rasagiline Mesylate Generic | 189 | 482 | 57 | $47K |
| Mirtazapine Generic | 163 | 436 | 58 | $2,683 |
| Rivastigmine Rivastigmine Tartrate | 162 | 305 | 36 | $11K |
| Nuplazid Pimavanserin Tartrate | 133 | 153 | 17 | $746K |
| Gocovri Amantadine Hcl | 102 | 140 | 18 | $307K |
| Midodrine Hcl Generic | 80 | 152 | 21 | $4,457 |
| Quetiapine Fumarate Generic | 68 | 130 | 19 | $1,632 |
| Clonazepam Generic | 66 | 133 | 37 | $865 |
| Modafinil Generic | 59 | 81 | 24 | $7,886 |
| Amantadine Amantadine Hcl | 39 | 65 | Under 11 | $3,784 |
| Nourianz Istradefylline | 30 | 32 | Under 11 | $60K |
| Gabapentin Generic | 28 | 40 | Under 11 | $431 |
Brand drugs: 712 claims; generic drugs: 1,802 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Catherine M Claro $215 ($215 in general payments such as food, travel and fees) from 3 companies. The largest payer was Abbvie Inc. with $165.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.